Cross-sectional study of reversible airway obstruction in LAM: better evidence is needed for bronchodilator and inhaled steroid use

Thorax. 2019 Oct;74(10):999-1002. doi: 10.1136/thoraxjnl-2019-213338. Epub 2019 Jul 30.

Abstract

Lymphangioleiomyomatosis can be associated with reversible airflow obstruction and although no guidelines around reversibility testing or inhaled therapy exist, many patients receive bronchodilators and inhaled corticosteroids. To better identify those who may benefit, we examined bronchodilator reversibility and inhaled therapy in a national cohort of 213 subjects. 20% of those tested had airway reversibility by standard criteria. 55% of patients used 13 different combinations of bronchodilators and inhaled corticosteroids. Increasing inhaler classes were associated with reversibility and more rapid FEV1 decline. Reversibility testing should be performed in all patients and inhaled therapy should be formally studied.

Keywords: rare lung diseases.

MeSH terms

  • Administration, Inhalation
  • Adult
  • Airway Obstruction / diagnosis
  • Airway Obstruction / drug therapy*
  • Airway Obstruction / etiology
  • Albuterol / administration & dosage*
  • Bronchodilator Agents / administration & dosage
  • Cross-Sectional Studies
  • Drug Therapy, Combination
  • Female
  • Follow-Up Studies
  • Forced Expiratory Volume / drug effects*
  • Glucocorticoids / administration & dosage*
  • Humans
  • Lung / drug effects
  • Lung / physiopathology*
  • Lung Neoplasms / complications*
  • Lung Neoplasms / diagnosis
  • Lung Neoplasms / physiopathology
  • Lymphangioleiomyomatosis / complications*
  • Lymphangioleiomyomatosis / diagnosis
  • Lymphangioleiomyomatosis / physiopathology
  • Middle Aged
  • Retrospective Studies
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • Bronchodilator Agents
  • Glucocorticoids
  • Albuterol